Tag

Pharma Industry

All articles tagged with #pharma industry

politics12 days ago•2 min saved

Trump to unveil voluntary drug-price discounts tied to foreign prices

President Trump is set to announce that about a dozen drugmakers will voluntarily lower prices on outpatient drugs, expanding the administration’s push to tie U.S. prices to cheaper foreign rates under its 'most favored nation' policy. The effort follows deals with roughly 17 pharma companies over the past year and a May 2025 executive order reviving the policy. Participating manufacturers would offer discounts to state Medicaid programs (optional participation) and may be exempt from Medicare discount pilots, as part of a broader strategy to curb healthcare costs ahead of elections, while drugmakers expand direct-to-consumer channels such as the TrumpRx portal.

via CNBC|

#drug-pricing #medicaid #most-favored-nation

business1 month ago•2 min saved

Trump eyes escalating tariffs on generics to push U.S. production onshore

Trump outlined a phased tariff plan on imported generic drugs: zero tariffs for two years starting Aug 1, 2026, then a 100% levy in Aug 2028 and 200% a year later, while tariffs on patented drugs stay the same. The move aims to force generic manufacturers to relocate production to the U.S. as part of a broader push to lower drug prices and reshape supply chains, amid ongoing dynamics with India and China in pharma.

via CNBC|

#business #generic-drugs #onshoring

business6 months ago•3 min saved

Merck Restructures to Stand Up a Dedicated Oncology Unit Ahead of Keytruda's Patent Cliff

Merck is splitting its human health business into two divisions—a dedicated oncology unit to oversee cancer therapies (including Keytruda) and a separate specialty pharma and infectious diseases unit for non-cancer products and vaccines—part of a strategy to sharpen growth after Keytruda's looming patent cliff. The company cites expectations of continued leadership in oncology and potential multi-brand growth, highlighting leadership changes: Jannie Oosthuizen will run the oncology and international unit, while Brian Foard heads the new specialty/pharma/infectious diseases unit, with Chirfi Guindo in a policy/communications role. Merck aims to sustain long-term oncology leadership and push growth through its pipeline, with executives signaling potential of more than $70B in annual revenue mid-decade.

via Fierce Pharma|

#business #corporate-reorganization #keytruda

health1 year ago•1 min saved

Merck withdraws from UK research, cancels London £1bn facility

Merck is halting its research operations in the UK and abandoning a new London research center due to frustrations with the UK's medicine pricing and support policies, highlighting concerns from the pharma industry about the country's attractiveness for research investment.

via statnews.com|

#health #london #medicines-pricing

health2 years ago•5 min saved

The Global Threat of Dengue: Killer Mosquitoes Establishing in Europe

The rise of dengue in Europe poses a public health threat but also presents a market opportunity for dengue vaccines and treatments. However, experts warn that this could exacerbate the access gap for low- and middle-income countries, as pharmaceutical companies may develop tools that are less effective in high-burden countries or wealthy nations may hoard medicines and vaccines. Climate change and migration have allowed mosquitoes that transmit dengue to establish themselves in Europe. While increased investment in neglected diseases is promising, there is concern that the products developed may not be globally relevant or prioritize the needs of countries where dengue is endemic. The mistakes made during the COVID-19 pandemic highlight the potential challenges in ensuring accessibility and affordability of these tools.

via POLITICO Europe|

#access-gap #dengue #europe

business3 years ago•0 min saved

CVS to Close Clinical Trial Business and Mobile Store

CVS is shutting down its clinical trials unit, which was launched in May 2021 to support clinical trials for experimental COVID-19 vaccines and treatments during the pandemic. The move is aimed at focusing on the company's core business, and a full exit is expected by December 31, 2024. CVS confirmed the decision, stating that it continually evaluates its portfolio of assets to ensure they are aligned with its long-term strategic priorities.

via Seeking Alpha|

#business #business-strategy #clinical-trials